Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AS37 adjuvanted hepatitis B vaccine in healthy adults
NCT05561673Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of AS37 in hepatitis B (HBV) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Solicited Administration Site Adverse Events After Dose 1 at 14 days, Number of Participants With Solicited Administration Site Adverse Events After Dose 2 at 14 days and 21 more. Started Oct 2022; status: completed.
02
Drugs
AS37
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05561673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561673.